文献速递乳腺癌头颈与中枢神经肿瘤

来那替尼联合ado-trastuzumab emtansine治疗经治及初治HER2阳性乳腺癌脑转移:转化乳腺癌研究联盟试验022

Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022.
PubMed 文献 · Ann Oncol · 2024-07-06

这项多中心II期研究纳入可测量HER2阳性乳腺癌脑转移患者,分为初治(4A)、局部中枢神经系统治疗后进展且未用过T-DM1(4B)和用过T-DM1(4C)三组,接受来那替尼160 mg每日联合T-DM1 3.6 mg/kg每21天静脉给药。各队列颅内客观缓解率分别为33.3%、35.3%和28.6%,腹泻为最常见3级毒性(22.7%),中位总生存分别为30.2、23.3和20.9个月。

要点

  • 来那替尼联合T-DM1在HER2阳性乳腺癌脑转移中观察到颅内活性,包括既往用过T-DM1者。
  • 队列4A、4B、4C的颅内客观缓解率分别为33.3%、35.3%和28.6%。
  • 腹泻是最常见3级毒性,发生率为22.7%。

核心结论

  • 来那替尼联合T-DM1在HER2阳性乳腺癌脑转移中观察到颅内活性,包括既往用过T-DM1者,提示来那替尼的协同效应。
  • 数据为来那替尼为基础的联合方案用于HER2阳性乳腺癌脑转移患者提供了额外证据,即使这些患者接受过大量既往治疗。

研究设计与样本

  • 多中心II期研究,纳入可测量HER2阳性乳腺癌脑转移患者,分三个平行入组队列:4A为初治脑转移,4B为局部中枢神经系统治疗后进展且未用过T-DM1,4C为局部中枢神经系统治疗后进展且用过T-DM1。
  • 治疗方案为来那替尼160 mg每日联合T-DM1 3.6 mg/kg静脉给药每21天一次,第1周期要求腹泻预防。
  • 主要终点为按队列评估的神经肿瘤脑转移缓解评估(RANO-BM),同时评估总生存和毒性。
  • 2018年至2021年间,队列4A、4B、4C分别入组6例、17例和21例;因入组缓慢提前终止入组。

主要发现

  • 队列4A、4B、4C的颅内客观缓解率分别为33.3%(95%CI 4.3%至77.7%)、35.3%(95%CI 14.2%至61.7%)和28.6%(95%CI 11.3%至52.2%)。
  • 38.1%至50%的患者疾病稳定≥6个月或达到缓解。
  • 腹泻是最常见的3级毒性,发生率为22.7%。
  • 中位总生存:队列4A为30.2个月(95%CI 21.9至未达到),队列4B为23.3个月(95%CI 17.6至未达到),队列4C为20.9个月(95%CI 14.9至未达到)。

局限性

  • 因入组缓慢提前终止入组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment options for human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases (BCBMs) remain limited. We previously reported central nervous system (CNS) activity for neratinib and neratinib-capecitabine. Preclinical data suggest that neratinib may overcome resistance to ado-trastuzumab emtansine (T-DM1) when given in combination. In Translational Breast Cancer Research Consortium (TBCRC) 022's cohort 4, we examined the efficacy of neratinib plus T-DM1 in patients with HER2-positive BCBM. PATIENTS AND METHODS: In this multicenter, phase II study, patients with measurable HER2-positive BCBM received neratinib 160 mg daily plus T-DM1 3.6 mg/kg intravenously every 21 days in three parallel-enrolling cohorts [cohort 4A-previously untreated BCBM, cohorts 4B and 4C-BCBM progressing after local CNS-directed therapy without (4B) and with (4C) prior exposure to T-DM1]. Cycle 1 diarrheal prophylaxis was required. The primary endpoint was the Response Assessment in Neuro-Oncology-Brain Metastases (RANO-BM) by cohort. The overall survival (OS) and toxicity were also assessed. RESULTS: Between 2018 and 2021, 6, 17, and 21 patients enrolled in cohorts 4A, 4B, and 4C. Enrollment was stopped prematurely for slow accrual. The CNS objective response rate in cohorts 4A, 4B, and 4C was 33.3% [95% confidence interval (CI) 4.3% to 77.7%], 35.3% (95% CI 14.2% to 61.7%), and 28.6% (95% CI 11.3% to 52.2%), respectively; 38.1%-50% experienced stable disease for ≥6 months or response. Diarrhea was the most common grade 3 toxicity (22.7%). The median OS was 30.2 [cohort 4A; 95% CI 21.9-not reached (NR)], 23.3 (cohort 4B; 95% CI 17.6-NR), and 20.9 (cohort 4C; 95% CI 14.9-NR) months. CONCLUSIONS: We observed intracranial activity for neratinib plus T-DM1, including those with prior T-DM1 exposure, suggesting synergistic effects with neratinib. Our data provide additional evidence for neratinib-based combinations in patients with HER2-positive BCBM, even those who are heavily pretreated.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Freedman RA, Heiling HM, Li T, et al. Neratinib and ado-trastuzumab emtansine for pretreated and untreated human epidermal growth factor receptor 2 (HER2)-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium trial 022. Ann Oncol. 2024. PMID: 38977064. doi:10.1016/j.annonc.2024.07.245

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。